Crossmark

Colchicine effectively attenuates inflammatory biomarker high-sensitivity C-reactive protein (hs-CRP) in patients with non-ST-segment elevation myocardial infarction: a randomised, double-blind, placebo-controlled clinical trial

Crossref DOI link: https://doi.org/10.1007/s10787-021-00865-0

Published Online: 2021-08-21

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gholoobi, Arash

Askari, Vahid Reza

Naghedinia, Hossein

Ahmadi, Mostafa

Vakili, Vida

Baradaran Rahimi, Vafa https://orcid.org/0000-0003-2320-5095
Funding

Funding for this research was provided by:

mashhad university of medical sciences (970561)
License Information

Text and Data Mining valid from 2021-08-21

Version of Record valid from 2021-08-21
More Information

Article History

Received: 21 July 2021

Accepted: 7 August 2021

First Online: 21 August 2021

Declarations

:

: The authors declare that there is no conflict of interest.

: This study was confirmed by the ethics committee of Mashhad University of Medical Sciences (approval code. IR. MUMS. MEDICAL. REC. 1398. 088). Furthermore, this trial was registered at (IRCT20190601043780N1).

: All participants received and signed written informed consent before their inclusion in the study.

: All the authors gave consent for the publication of this study in the journal.

Document is current

Any future updates will be listed below